Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.
For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).
FDA inspection outcomes across these CDMOs: 4 NAI (no action), 4 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Germany (10), United States (7), UNITED STATES (4), China (1).
Last updated 2026-09-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
#
CDMO
Signal Score
Quality
FDA · GMP
Capacity
Programs
1
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
81.8
98.7
2 insp · 2 GMP
—
22 programs
2
MB
Miltenyi Biotec
Bergisch Gladbach, Germany
73.0
100.0
0 insp · 2 GMP
—
8 programs
3
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.
What makes the German CDMO cluster distinctive within Europe?
Germany's CDMO base combines three attributes that shape sponsor decisions: (1) strong biologics + advanced-therapy depth — BioNTech's Marburg site is one of the largest single-facility mRNA operations globally, Boehringer Ingelheim BioXcellence operates commercial-scale biologics at Biberach, and Rentschler carries deep mAb + biosimilar experience; (2) engineering discipline — German pharmaceutical manufacturing has a reputation for process rigor that translates into strong FDA and EMA inspection outcomes; (3) proximity to European pharmaceutical R&D centers, which reduces tech-transfer coordination cost. German CDMOs generally hold BfArM + EMA + MHRA + FDA certifications concurrently for global-market-supplying facilities.
Which German CDMOs specialize in advanced-therapy modalities (viral vector, cell therapy, mRNA)?
Germany hosts substantial advanced-therapy CDMO capacity. Cross-reference with modality pages to filter: mRNA CDMOs (BioNTech Manufacturing Services is Germany's largest), AAV CDMOs, lentiviral CDMOs, cell therapy CDMOs, or the viral vector umbrella. The individual CDMO profile pages surface facility-level modality coverage — critical for advanced-therapy programs where the specific German site's containment class and analytics platform matter more than country-level aggregates.
German CDMOs supplying US and Asian markets
German CDMOs with FDA and Asian regulator inspection history qualify to supply global markets; those without cross-jurisdictional inspection posture are typically limited to EU and MHRA scope. Cross-check with the US region ranking and Asia region ranking to identify German-headquartered CDMOs with global footprint. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so cross-jurisdictional German CDMOs typically rank higher on this pillar than EU-only competitors.
By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Merck KGaA / MilliporeSigma (CDMO), Miltenyi Biotec, Minaris Advanced Therapies. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 3 Cell & Gene Therapy CDMOs with FDA inspection records and 14 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.